FindTrial
Sign In

A safety and Immunogenicity Study of IR103 HIV-1 Antigen plus Amplivax TM in IFA Comapared to Remune R HIV-1 antigen in IFA in Antiretroviral Naive HIV-1 Infected Subjects

A safety and Immunogenicity Study of IR103 HIV-1 Antigen plus Amplivax TM in IFA Comapared to Remune R HIV-1 antigen in IFA in Antiretroviral Naive HIV-1 Infected Subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-005050-31-IT
Enrollment
Unknown
Registered
2007-02-14
Start date
2005-07-21
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

agent able to generate HIV-specific immune responses in antiretroviral naive HIV infected subjects.

Interventions

Product Name: REMUNE Pharmaceutical Form: Emulsion for injection Current Sponsor code: HIV-1 IMMUNOGEN Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 10- Product

Sponsors

THE IMMUNE RESPONSE CORPORATION
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026